Abbott announced that its FreeStyle Libre 3 sensor is now compatible with the mylife Loop solution from partners, Ypsomed and CamDiab, creating a smart, automated process to deliver insulin based on real-time glucose data. This automated insulin delivery system (AID) solution is now available in Germany and will be available in additional European countries beginning in 2023.
Integrating CamDiab's CamAPS FX mobile app and Ypsomed's mylifeTM YpsoPump with accurate, real-time data from Abbott's FreeStyle Libre 3 sensor, the connected solution continuously monitors a person's glucose levels, and automatically adjusts and delivers the right amount of insulin at the right time, removing the guesswork of insulin dosing and helping people with diabetes reach better treatment targets.
"Our FreeStyle Libre portfolio is already helping to improve the lives of 4.5 million people around the world who are living with diabetes," said Jared Watkin, senior vice president of Abbott's diabetes care business. "We're partnering with diabetes and digital health technology leaders like Ypsomed and CamDiab to deliver new innovative solutions that make diabetes care as easy as possible, so people can spend less time worrying about their diabetes and more time living."
This AID solution is currently not available in the United States.
In addition to partnering with Ypsomed and CamDiab, Abbott is working to make the FreeStyle Libre platform interoperable with other leading insulin delivery systems.